Last updated: February 21, 2026
Case Overview
This case involves the Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund (Plaintiff), suing Allergan, Inc. (Defendant), over alleged defects in certain medical devices. Filed in the United States District Court for the Southern District of Florida, the case number is 1:18-cv-00969.
Claim Type: Product liability and negligence concerning allegedly defective medical devices.
Core Allegations: The Plaintiff claims Allergan’s devices caused injuries, allegedly due to design defects, failure to warn, and manufacturing deficiencies.
Procedural Chronology
- Complaint Filed: March 20, 2018
- Defendant’s Response: Motion to dismiss filed June 15, 2018
- Amended Complaint: Filed September 3, 2018, after initial dismissal motion
- Key Motions: Summary judgment motions filed by Allergan in December 2020
- Discovery: Completed by mid-2021
- Trial Date: Set for August 2023, but later postponed
Claims and Legal Theories
| Claim Type |
Description |
| Design Defect |
Devices were inherently unsafe due to their design, when reasonable alternatives existed. |
| Failure to Warn |
Allergan did not adequately warn medical providers or patients of device risks. |
| Manufacturing Defect |
Variations in manufacturing led to unsafe devices. |
Defendant’s Defenses
- Preemption: Argues federal approval by the FDA preempts state-law claims.
- Failure to State a Claim: Claims legally insufficient or lack factual support.
- Assumption of Risk: Medical providers and patients were aware of risks.
Key Legal Issues
- Preemption Defense: Whether federal regulation, through the FDA’s approval process, precludes state law claims.
- Materiality of Warnings: Whether Allergan provided adequate warnings, considering available information at the time.
- Causation and Damages: Establishing direct link between devices and injuries.
Court Decisions and Outcomes
- Dismissal of Certain Claims: The court initially dismissed claims regarding alleged design defects, citing FDA approval as a barrier.
- Discovery Disputes: Several motions to compel discovery were filed, related to internal communications and adverse event reports.
- Summary Judgment: Allergan filed a motion arguing lack of causation; the court has yet to rule.
Recent Developments
In 2022, the court granted a defendant motion to exclude certain expert testimony on causation, which significantly impacts Plaintiff's case. As of late 2022, the case is scheduled for trial in August 2023, with procedural deadlines ongoing.
Industry and Legal Context
- Product Liability in Medical Devices: Preemption under the Medical Device Amendments (MDA) of the Federal Food, Drug, and Cosmetic Act (FDCA) is a common defense.
- Mass Tort Litigation Trends: Allergan faces other similar suits linked to its devices, contributing to the ongoing legal scrutiny.
Strategic Implications
- For Plaintiffs: Proving causation and inadequate warnings remains challenging against FDA-approved devices.
- For Defendants: Emphasizing regulatory preemption and highlighting FDA’s approval process as a competent safeguard.
- For Investors: The case’s resolution may influence Allergan’s liability exposure and financial standing.
Key Takeaways
- The case underscores the importance of the FDA’s approval process in product liability defenses.
- Causation evidence, especially expert testimony, is pivotal in medical device defect claims.
- Discovery disputes highlight the significance of internal communications in multidistrict litigation strategies.
- The outcome could impact similar litigation involving FDA-approved devices.
- Ongoing procedural developments suggest continued legal exposure for Allergan in related suits.
FAQs
1. How does FDA approval impact product liability claims?
FDA approval can preempt state law claims under the Medical Device Amendments, provided the device was safely approved for its intended use.
2. What are typical defenses used in medical device litigations?
Defendants often use preemption, warning adequacy, or manufacturing process safety to defend against liability claims.
3. What role does expert testimony play?
Expert testimony is essential to establish causation and defect claims; courts scrutinize its admissibility closely.
4. Have any claims been dismissed in this case?
Yes, initial design defect claims were dismissed based on preemption, but some claims remain active.
5. Could the outcome influence future litigations?
Yes, particularly concerning the scope of FDA’s preemption and the admissibility of causation evidence.
Sources
[1] Court docket for Civil Action No. 1:18-cv-00969, Southern District of Florida (2022).
[2] FDA Medical Device Regulations, 21 CFR Parts 800-898.
[3] U.S. Food and Drug Administration. (2019). “Medical Device Reporting (MDR): How to report adverse events and other problems.”
[4] Lambert, P. (2021). “Product liability and FDA preemption: Trends in medical device litigation.” Journal of Health Law, 54(3), 145-170.
[5] U.S. Supreme Court. (2008). Riegel v. Medtronic, Inc., 552 U.S. 312.
